No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy

byKathleen Lau

March 18, 2021

in StudyGraphics

Rapid antigen-based home testing reduced SARS-CoV-2 transmission and mortality

RelatedReports

Adalimumab aids in control of noninfectious uveitis

Chronic Disease

Younger age and systemic metastases may independently predict survival among patients with choroidal metastases

August 3, 2026

Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Chronic Disease

A digital mental health intervention may improve anxiety in breast cancer survivors

July 31, 2026

No significant increased risk of bladder cancer with pioglitazone use

Oncology

All-oral chemotherapy regimen tolerable and efficacious for newly diagnosed acute myeloid leukemia

July 23, 2026

Radiation plus hormone therapy may improve prostate cancer survival

Chronic Disease

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

July 22, 2026

#VisualAbstract: Salpingo-oophorectomy may reduce short-term risk of breast cancer in women with BRCA1 and BRCA2 variants

#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)

Parents often unaware of adolescents’ suicidal thoughts

Ketamine infusion significantly reduces depressive symptoms among adolescents with treatment-resistant depression

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy

RELATED REPORTS

Rapid antigen-based home testing reduced SARS-CoV-2 transmission and mortality

#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)

RelatedReports

Recent Reports